Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Operating Expenses

Last Annual Value

9.22M

3-Year CAGR

11%

5-Year CAGR

121%

10-Year CAGR

49%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Operating Expenses

ANEB · NASDAQ
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
9.22M
-7.8%20.6%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
23.24M
-17.3%-14.3%N/A
26.85M
18.5%81.8%N/A
145.01M
-21.5%-7.7%N/A
76.26M
11.3%18.4%2.7%
79.90M
-14.1%13.9%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
9.72M
75.5%51.1%N/A
95.69M
23.4%21.0%N/A
15.10M
-4.1%-10.9%4.0%
57.28M
18.3%-8.7%N/A
36.51M
-16.2%-2.8%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72